The GLP-1 Data Series

Every major trial's headline results in one place — weight loss, completion rates, cardiovascular outcomes, and adverse events.

List prices, net costs after rebates, consumer self-pay, and Medicare negotiated prices — side by side for every drug. Includes an interactive cost calculator.

Persistence rates from every published study, from 30 days through 3 years — including why reported 12-month rates range from 10% to 63% depending on the source, and what's actually improved since 2021.

Weight regain data from every trial withdrawal and extension study, plus metabolic parameter rebound. What the evidence says about indefinite treatment — and what that means when 92% of patients stop within 3 years.

The only published real-world analysis found no medical cost offsets — costs actually increased $1,338 per member. How the SELECT trial counterargument falls apart, and what honest ROI modeling looks like.

GI adverse event rates from every pivotal trial, discontinuation-for-tolerability percentages, and the emerging signals on muscle mass loss, gallbladder disease, and pancreatitis — plus how real-world rates compare to the controlled trial numbers.

What large real-world studies actually show about GLP-1 weight loss at one year — and why the numbers are so different from clinical trials. Evidence from Cleveland Clinic, Truveta, Vanderbilt, Mayo Clinic, and the Danish national registry.